It Has Been A Long Farewell To The Medicines Company
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
You may also be interested in...
Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
Silence Signs Takeda Deal And Sets Sights On US
The resignation of David Horn Solomon last month was a setback for Silence but the company believes it will benefit from the growing prominence given to RNAi technology.
Early Assets Excite At Novartis R&D Day
NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.